摘要
目的分析疏风解毒胶囊联合布地格福吸入气雾剂在慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)中的临床效果。方法选择2022年2月至2023年1月四川绵阳四0四医院(绵阳市第一人民医院)收治的122例AECOPD患者作为研究对象,采用随机数字表法将其分成研究组(n=61)和对照组(n=61)。2组患者均接受规范化基础治疗。对照组在此基础上另给予布地格福吸入气雾剂治疗,研究组在对照组的基础上另给予疏风解毒胶囊治疗。2组患者均治疗14 d。比较2组患者临床疗效、第一秒用力呼气容积(forced expiratory volume in one second,FEV1)、呼气峰值流速(peak expiratory flow,PEF)、用力肺活量(forced vital capacity,FVC)、血清C反应蛋白(C-reac-tive protein,CRP)、血清淀粉样蛋白A(serum amyloid A,SAA)、血清降钙素原(procalcitonin,PCT)、气道壁厚度/外径比值(thickness-diameter ratio,TDR)、气道面积/总横截面积比值(percentage of wall area,WA)及用药安全性。结果研究组患者总有效率(93.44%)高于对照组(75.41%),差异有统计学意义(P<0.05)。治疗后,2组患者FEV1、PEF、FVC水平均升高,且研究组更高,差异均有统计学意义(P<0.05)。治疗后,2组患者血清CRP、SAA、PCT水平均降低,且研究组更低,差异均有统计学意义(P<0.05)。治疗后,2组患者TDR、WA均降低,且研究组更低,差异均有统计学意义(P<0.05)。2组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。结论疏风解毒胶囊联合布地格福吸入气雾剂治疗AECOPD疗效确切,可改善患者肺功能和气道重塑指标,减轻炎症反应,降低血清SAA水平,且安全可靠。
Objective To analyze the clinical effect of Shufeng Jiedu capsule combined with Budesonide inhalation aerosol on acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods A total of 122 AECOPD patients admitted to the 404th Hospital of Mianyang,Sichuan Province from February 2022 to January 2023 were selected and divided into study group(n=61)and control group(n=61)by random number table method.All the patients received standardized basic treatment.The control group was also given Budesonide inhalation aerosol,and the study group was given Shufeng Jiedu capsule plus Budesonide inhalation aerosol.The patients in both groups were treated for 14 d.The clinical efficacy,forced expiratory volume in one second(FEV1),peak expiratory flow(PEF),forced vital capacity(FVC),serum C-reactive protein(CRP),serum amyloid A(SAA),serum procalcitonin(PCT),airway wall thickness-diameter ratio(TDR),percentage of wall area(WA)and drug safety were compared between the two groups.Results The total effective rate of the study group was significantly higher than that of the control group(93.44%vs.75.41%,P<0.05).After treatment,the levels of FEV1,PEF and FVC were increased in both groups(P<0.05),especially in the study group(P<0.05).After treatment,serum levels of CRP,SAA and PCT,TDR and WA were decreased in both groups(P<0.05),especially in the study group(all P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Shufeng Jiedu Capsule combined with Budesonide inhalation aerosol is effective,safe and reliable in the treatment of AECOPD.It can improve lung function and airway remodeling indexes,alleviate inflammation and reduce SAA level.
作者
李帆
张艳
刘琬薰
刘晓华
Li Fan;Zhang Yan;Liu Wanxun;Liu Xiaohua(Department of Respiratory and Critical Care Medicine,The 404th Hospital of Mianyang,Mianyang 621000,China)
出处
《海军医学杂志》
2024年第5期526-530,共5页
Journal of Navy Medicine
关键词
疏风解毒胶囊
布地格福吸入气雾剂
慢性阻塞性肺疾病
急性加重期
临床疗效
Shufeng Jiedu Capsule
Budesonide inhalation aerosol
Chronic obstructive pulmonary disease
Acute exacerbation
Clinical effect
